US5169639A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Controlled release verapamil tablets
Assignee: Penwest Pharmaceuticals Co
•
Filing: 1991-07-25
•
Granted: 1992-12-08
•
Expires: 2011-07-25
Abstract
Abstract Controlled release verapamil tablets are disclosed. The tablets include an excipient having a hydrophilic material, preferably containing a mixture of xanthan gum/locust bean gum, and an inert diluent.
Inventors
- 👤 Anand R. Baichwal
- 👤 John N. Staniforth
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 18:16
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/14; A61K9/16; A61K9/20; A61K9/2004; A61K9/2022; A61K9/205; A61K31/00; A61K31/275; A61K9/2013; A61K9/2018; A61K9/2072; A61K9/2077; A61P; A61P9/00; A61P9/06; A61P9/12
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
106 words
A tablet for the controlled release of verapamil in the gastro-intestinal tract, comprising: a controlled release excipient comprising a hydrophilic gum matrix comprising a xanthan gum and locust bean gum in a ratio of from about 3:1 to about 1:3, and an inert diluent selected from the group consisting of a monosaccharide, a disaccharide, a polyhydric alcohol, and mixtures thereof, the ratio of said inert diluent to said hydrophilic gum matrix being from about 4:1 to about 0.67:1; and an effective amount of verapamil to render a desired therapeutic effect, the ratio of verapamil to said hydrophilic gum matrix being from about 3:1 to about 1:3.
Claim 2
Dependent Claim
106 words
A tablet for the controlled release of verapamil in the gastro-intestinal tract, comprising: a controlled release excipient comprising a hydrophilic gum matrix comprising a xanthan gum and locust bean gum in a ratio of from about 3:1 to about 1:3, and an inert diluent selected from the group consisting of a monosaccharide, a disaccharide, a polyhydric alcohol, and mixtures thereof, the ratio of said inert diluent to said hydrophilic gum matrix being from about 4:1 to about 0.67:1; and an effective amount of verapamil to render a desired therapeutic effect, the ratio of verapamil to said hydrophilic gum matrix being from about 3:1 to about 1:3.
Claim 3
Dependent Claim
19 words
The tablet of claim 1, wherein the verapamil is dry granulated with said controlled release excipient prior to tableting.
Claim 4
Dependent Claim
19 words
The tablet of claim 1, wherein the verapamil is wet granulated with said controlled release excipient prior to tableting.
Claim 5
Dependent Claim
57 words
The tablet of claim 1, wherein a first portion of the verapamil is dry granulated with a first portion of said controlled release excipient, and a second portion of the verapamil is wet granulated with a second portion of said controlled release excipient, said dry granulated portion and said wet granulated portion being combined prior to tableting.
Claim 6
Dependent Claim
18 words
The tablet of claim 1, wherein the ratio of xanthan gum to locust bean gum is about 1:1.
Claim 7
Dependent Claim
84 words
A tablet for the controlled release of verapamil in the gastro-intestinal tract, comprising: from about 45 to about 70 percent of a controlled release excipient comprising from about 25 to about 55 percent of a hydrophilic gum matrix comprising a xanthan gum and locust bean gum in a ratio of about 1:1, and an inert diluent selected from the group consisting of a monosaccharide, a disaccharide, a polyhydric alcohol, and mixtures thereof; and an effective amount of verapamil to render a desired therapeutic effect.
Claim 8
Dependent Claim
84 words
A tablet for the controlled release of verapamil in the gastro-intestinal tract, comprising: from about 45 to about 70 percent of a controlled release excipient comprising from about 25 to about 55 percent of a hydrophilic gum matrix comprising a xanthan gum and locust bean gum in a ratio of about 1:1, and an inert diluent selected from the group consisting of a monosaccharide, a disaccharide, a polyhydric alcohol, and mixtures thereof; and an effective amount of verapamil to render a desired therapeutic effect.
Claim 9
Dependent Claim
21 words
The tablet of claim 6, wherein the ratio of verapamil to said hydrophilic material is from about 1.0:0.4 to about 1.0:0.7.
Claim 10
Independent Claim
137 words
A method for preparing a controlled release verapamil formulation, comprising: preparing a hydrophilic gum matrix comprising xanthan gum and locust bean gum in a ratio of about 1:1; mixing said hydrophilic gum matrix with an inert diluent selected from the group consisting of a monosaccharide, a disaccharide, a polyhydric alcohol, and mixtures thereof, in a ratio of said inert diluent to said hydrophilic gum matrix from about 4:1 to about 0.67:1; combining the mixture of hydrophilic gum matrix/inert diluent with verapamil, such that the ratio of verapamil to said hydrophilic gum matrix/inert diluent mixture is from about 1.0:0.4 to about 1.0:0.7; and compressing the resultant mixture to form solid tablets having a desired dosage of verapamil to render a desired therapeutic effect, the verapamil being released according to a desired dissolution profile when exposed to gastric fluid.
Claim 11
Independent Claim
137 words
A method for preparing a controlled release verapamil formulation, comprising: preparing a hydrophilic gum matrix comprising xanthan gum and locust bean gum in a ratio of about 1:1; mixing said hydrophilic gum matrix with an inert diluent selected from the group consisting of a monosaccharide, a disaccharide, a polyhydric alcohol, and mixtures thereof, in a ratio of said inert diluent to said hydrophilic gum matrix from about 4:1 to about 0.67:1; combining the mixture of hydrophilic gum matrix/inert diluent with verapamil, such that the ratio of verapamil to said hydrophilic gum matrix/inert diluent mixture is from about 1.0:0.4 to about 1.0:0.7; and compressing the resultant mixture to form solid tablets having a desired dosage of verapamil to render a desired therapeutic effect, the verapamil being released according to a desired dissolution profile when exposed to gastric fluid.
Claim 12
Dependent Claim
20 words
The method of claim 8, wherein verapamil is combined with the mixture of hydrophilic gum matrix/inert diluent via wet granulation.
References Cited (Backward Citations)
US2993836A
Cited
US3079303A
Cited
US3074852A
Cited
US3133863A
Cited
US3147187A
Cited
US3388041A
Cited
GB1097207A
Cited
US3456049A
Cited
US3726690A
Cited
US3864469A
Cited
US3627583A
Cited
US3639169A
Cited
US3629393A
Cited
US3728445A
Cited
US4072535A
Cited
US3773920A
Cited
US3836618A
Cited
US3950508A
Cited
US3963832A
Cited
US4013820A
Cited
US4167558A
Cited
US4199560A
Cited
US4361545A
Cited
US4259314A
Cited
US4308251A
Cited
US4439453A
Cited
US4542011A
Cited
US4424235A
Cited
US4525345A
Cited
US4389393A
Cited
US4389393B1
Cited
US4556678A
Cited
WO1984000104A1
Cited
US4698264A
Cited
US4698101A
Cited
US4692337A
Cited
US4717713A
Cited
US4623394A
Cited
US4590062A
Cited
US4695467A
Cited
EP0180364A2
Cited
US4762702A
Cited
US4695463A
Cited
WO1987000044A1
Cited
GB2178658A
Cited
US4755389A
Cited
US4704285A
Cited
EP0234670B1
Cited
WO1987005212A1
Cited
US4855143A
Cited
GB2188843A
Cited
US4829056A
Cited
US4828836A
Cited
US4803077A
Cited
US4792452A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-12-08 | 1996-06-08 | 1996-12-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-12-08 | 2000-06-08 | 2000-12-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-12-08 | 2004-06-08 | 2004-12-08 | $7700.00 | Window Closed / Lapsed |